Phase 2 N=7 Treatment

Thalidomide Low Threshold in Epilepsy

Refractory Epilepsy

Bottom Line

View on ClinicalTrials.gov: NCT01061866 ↗

Enrolled (actual)

Serious AEs

28.6%

Results posted

Feb 2010

Primary outcome: Primary: Change From Baseline in the Mean Number of Daily Seizures at 1 Year. — 9 Number of Seizures — p=<0.02

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: 3-phthalimidoglutarimide (Thalidomide) (Drug)
Age: Pediatric, Adult · 17+ yrs
Sex: Male
Sponsor: National Institute of Neurology and Neurosurgery, Mexico
Primary completion: Jun 2007

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline in the Mean Number of Daily Seizures at 1 Year.	9	<0.02 sig

Summary

The purpose of this study is to determine whether thalidomide is effective in the refractory epilepsy treatment.

Eligibility Criteria

Inclusion Criteria

Refractory Epilepsy, males

Exclusion Criteria

Females, peripheric neuropathy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01061866). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.